Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Sareum Holdings Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sareum Holdings.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	16.3%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Here's Why We're Not Too Worried About Sareum Holdings' (LON:SAR) Cash Burn Situation

Aug 24

What Type Of Shareholders Own The Most Number of Sareum Holdings plc (LON:SAR) Shares?

Dec 23

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Sareum Holdings yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

AIM:SAR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (GBP Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	N/A	-4	N/A	-4	1
12/31/2023	N/A	-4	-5	-5	N/A
9/30/2023	N/A	-4	-4	-4	N/A
6/30/2023	N/A	-3	-3	-3	N/A
3/31/2023	N/A	-3	-3	-3	N/A
12/31/2022	N/A	-3	-3	-3	N/A
9/30/2022	N/A	-2	-2	-2	N/A
6/30/2022	N/A	-2	-2	-2	N/A
3/31/2022	0	-2	-2	-2	N/A
12/31/2021	0	-2	-2	-2	N/A
9/30/2021	0	-2	-2	-2	N/A
6/30/2021	0	-1	-2	-2	N/A
3/31/2021	0	-1	-1	-1	N/A
12/31/2020	0	-1	-1	-1	N/A
9/30/2020	0	-1	-1	-1	N/A
6/30/2020	0	-1	-1	-1	N/A
3/31/2020	0	-1	-1	-1	N/A
12/31/2019	N/A	-1	-1	-1	N/A
9/30/2019	N/A	-1	-1	-1	N/A
6/30/2019	N/A	-1	-1	-1	N/A
3/31/2019	N/A	-1	-1	-1	N/A
12/31/2018	N/A	-2	-1	-1	N/A
9/30/2018	N/A	-1	-2	-2	N/A
6/30/2018	N/A	-1	-2	-2	N/A
3/31/2018	N/A	-1	-1	-1	N/A
12/31/2017	N/A	-1	-1	-1	N/A
9/30/2017	N/A	0	N/A	0	N/A
6/30/2017	N/A	0	N/A	1	N/A
3/31/2017	N/A	0	N/A	1	N/A
12/31/2016	N/A	0	N/A	1	N/A
9/30/2016	N/A	-1	N/A	0	N/A
6/30/2016	N/A	-1	N/A	-1	N/A
3/31/2016	N/A	-1	N/A	-1	N/A
12/31/2015	N/A	-1	N/A	-1	N/A
9/30/2015	N/A	-1	N/A	-1	N/A
6/30/2015	N/A	-1	N/A	-1	N/A
3/31/2015	N/A	-1	N/A	-1	N/A
12/31/2014	N/A	-1	N/A	-1	N/A
9/30/2014	N/A	-1	N/A	-1	N/A
6/30/2014	N/A	-1	N/A	-1	N/A
3/31/2014	N/A	-1	N/A	-1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if SAR's forecast earnings growth is above the savings rate (1.9%).

Kazançlar ve Piyasa: Insufficient data to determine if SAR's earnings are forecast to grow faster than the UK market

Yüksek Büyüme Kazançları: Insufficient data to determine if SAR's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if SAR's revenue is forecast to grow faster than the UK market.

Yüksek Büyüme Geliri: Insufficient data to determine if SAR's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if SAR's Return on Equity is forecast to be high in 3 years time

Sareum Holdings Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Forecast to breakeven in 2026

Sareum Holdings plc Provides Earnings Guidance for the Year to 30 June 2023

Sareum Holdings plc Provides Consolidated Sales Guidance for the Fiscal Year 2022

Sareum Holdings plc Provides Financial Guidance for Fiscal 2021

Recent updates

Sareum Holdings plc Receives Notice of Allowance from the China National Intellectual Property Administration

Sareum Holdings plc Receives A Notice of Allowance from the US Patent and Trademark Office for A Patent on SDC-1801

Sareum Holdings plc Announces Transition of Chief Executive Officer

Sareum Holdings plc Announces Positive Data from SDC-1801 Phase 1 Clinical Trial

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Sareum Holdings plc has completed a Follow-on Equity Offering in the amount of £1.268973 million.

Sareum Holdings plc has filed a Follow-on Equity Offering in the amount of £0.1875 million.

New major risk - Market cap size

Forecast to breakeven in 2026

New major risk - Share price stability

Sareum Holdings plc Announces Completion of the Single Ascending Dose (SAD) Part and the Food Effect Study of its Phase 1a Clinical Trial for the Lead Programme SDC-1801

Sareum Holdings plc Provides Update on Operational Activities and Pipeline Progress

Sareum Holdings plc, Annual General Meeting, Dec 14, 2023

Sareum Holdings plc Initiates Food Effects Study in Phase 1a Trial for SDC-1801

New minor risk - Insider selling

New minor risk - Shareholder dilution

New minor risk - Financial data availability

Sareum Holdings plc to Report Fiscal Year 2023 Results on Oct 09, 2023

Sareum Holdings plc Starts Dosing First Subjects in the Multiple Ascending Dose Part of Phase 1a Clinical Trial for SDC-1801

Here's Why We're Not Too Worried About Sareum Holdings' (LON:SAR) Cash Burn Situation

Sareum Holdings plc Provides Earnings Guidance for the Year to 30 June 2023

New major risk - Share price stability

New minor risk - Market cap size

Sareum Holdings plc Announces the Commencement of A Phase 1a Clinical Trial for SDC-1801

We're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn Rate

Sareum Holdings plc, Annual General Meeting, Dec 16, 2022

Sareum Holdings plc Notes Publication of SRA737 Clinical Data

Insufficient new directors

Sareum Holdings plc Notes FDA Approval of First TYK2 Inhibitor

Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans

Sareum Submits Clinical Trial Authorisation Application to UK MHRA for Development of TYK2/JAK1 Inhibitor SDC-1801

Sareum Holdings plc Provides Consolidated Sales Guidance for the Fiscal Year 2022

Insufficient new directors

We Think Sareum Holdings (LON:SAR) Can Afford To Drive Business Growth

Sareum Holdings plc Announces European Patent Granted for Sareum’s SDC-1802

Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans

Insufficient new directors

Insufficient new directors

Founder exercised options and sold UK£123k worth of stock

We're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn Rate

Sareum Holdings plc Provides Financial Guidance for Fiscal 2021

We're Hopeful That Sareum Holdings (LON:SAR) Will Use Its Cash Wisely

Sareum Holdings plc Launched of Its AGILE Clinical Development Platform to Fund Phase 1 Trials and Fast-Track the Development of Potentially Ground-Breaking COVID-19 Treatments

Sareum Holdings plc Provides Update on FLT3+Aurora Kinase Inhibitor Programme

What Type Of Shareholders Own The Most Number of Sareum Holdings plc (LON:SAR) Shares?

Sareum Holdings plc Announces TYK2 as Key Causative Genetic Mechanism and Potential Target for Therapy

Sareum Holdings plc, Annual General Meeting, Dec 15, 2020

Sareum Holdings plc Announces That US Patent Allowance for Sareum's SDC-1802 TYK2/JAK1 Inhibitor

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin